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Abstract
Senescence is a permanent proliferation arrest in response to cell stress such as DNA damage. It contributes strongly to
tissue aging and serves as a major barrier against tumor development. Most tumor cells are believed to bypass the
senescence barrier (become ‘‘immortal’’) by inactivating growth control genes such as TP53 and CDKN2A. They also
reactivate telomerase reverse transcriptase. Senescence-to-immortality transition is accompanied by major phenotypic and
biochemical changes mediated by genome-wide transcriptional modifications. This appears to happen during
hepatocellular carcinoma (HCC) development in patients with liver cirrhosis, however, the accompanying transcriptional
changes are virtually unknown. We investigated genome-wide transcriptional changes related to the senescence-to-
immortality switch during hepatocellular carcinogenesis. Initially, we performed transcriptome analysis of senescent and
immortal clones of Huh7 HCC cell line, and identified genes with significant differential expression to establish a
senescence-related gene list. Through the analysis of senescence-related gene expression in different liver tissues we
showed that cirrhosis and HCC display expression patterns compatible with senescent and immortal phenotypes,
respectively; dysplasia being a transitional state. Gene set enrichment analysis revealed that cirrhosis/senescence-associated
genes were preferentially expressed in non-tumor tissues, less malignant tumors, and differentiated or senescent cells. In
contrast, HCC/immortality genes were up-regulated in tumor tissues, or more malignant tumors and progenitor cells. In
HCC tumors and immortal cells genes involved in DNA repair, cell cycle, telomere extension and branched chain amino acid
metabolism were up-regulated, whereas genes involved in cell signaling, as well as in drug, lipid, retinoid and glycolytic
metabolism were down-regulated. Based on these distinctive gene expression features we developed a 15-gene
hepatocellular immortality signature test that discriminated HCC from cirrhosis with high accuracy. Our findings
demonstrate that senescence bypass plays a central role in hepatocellular carcinogenesis engendering systematic changes
in the transcription of genes regulating DNA repair, proliferation, differentiation and metabolism.
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Introduction
Cellular senescence, a permanent loss of proliferative capacity
despite continued viability and metabolic activity, is a critical
feature of mammalian cells. It serves as a potent anti-tumor
mechanism but it may also contribute to tissue aging [1,2,3]. This
process was initially described in the form of replicative senescence
[4], or telomere-dependent senescence, that has later been
characterized as a DNA damage checkpoint response to the loss
of telomere integrity, because of progressive shrinkage of the
telomere DNA during cell replication [5]. Subsequently, telomere-
independent or premature forms of senescence have been
discovered. Thus, not only telomere attrition but also oncogene
activation [6], tumor suppressor gene inactivation, as well as
exposure to DNA-damaging agents can trigger senescence
responses [1]. Cellular processes leading to a senescence-type of
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cell proliferation arrest are mediated mainly by p53 and p16INK4A-
Rb signal transduction cascades [1,7,8]. Senescence response can
be delayed or bypassed by experimental activation of telomerase
reverse transcriptase (TERT), and/or inactivation of p53 and
p16INK4A-Rb pathways. This leads cells to an immortal state with
unlimited proliferation capacity [9]. Cells in pre-senescent,
senescent and immortal states display highly divergent transcrip-
tion patterns allowing them to exhibit distinct phenotypic and
biochemical features [10,11,12].
Human tumors frequently exhibit TERT activation and
inactivation of p53 and p16INK4A-Rb-mediated senescence control
pathways leading on the postulation that gain of cellular
immortality is one of their common features [13]. Hepatocellular
carcinoma (HCC) cells are also believed to acquire immortality,
particularly in patients with liver cirrhosis known to exhibit a
senescent phenotype [14,15]. Telomerase deficiency in mice
accelerates the development of experimentally induced cirrhosis
[16] and compromises liver regeneration [17]. The inactivation of
c-myc or reactivation of p53 in murine HCC cells induces
premature senescence leading to tumor regression [18,19]. These
findings infer that c-myc activation and p53 inactivation may serve
as a means to overcome senescence control, at least in murine
HCC tumors. Human liver cells do not express the TERT enzyme
and exhibit moderate telomere shortening during aging, yet
senescence markers usually remain negative in old liver tissues.
During chronic hepatitis, the development of cirrhosis is associated
with accelerated telomere shortening. Moreover, cirrhotic tissues
exhibit strong senescence-associated b-galactosidase (SA-b-Gal)
activity, suggesting that most hepatocytes in a cirrhotic liver
display a senescent phenotype [20,21,22,23]. In most human
HCC tumors TERT expression is positive, telomerase activity is
high and telomere length is short, but stabilized. However, a subset
of HCC tumors display high SA-b-Gal activity suggestive of
senescence arrest [14,20,24,25,26]. Thus, it appears that human
HCC cells, as opposed to cirrhotic hepatocytes, acquire an
immortal phenotype, although this has not yet been fully
demonstrated. In favor of this suggestion, the genes encoding
p53 and p16INK4A, two major players in senescence control, are
known to be inactivated by mutation and/or epigenetic silencing
in nearly 50% of HCCs [15]. However, several important
questions remain unanswered with regard to the relevance of
senescence escape or immortality in human HCC. Among others,
(i) a comprehensive list of genes associated with hepatocellular
senescence and immortality is lacking; (ii) the cellular processes
associated with senescence-related changes in cirrhosis and HCC
are not well-documented; (iii) the timing of senescence-to-
immortality transition during HCC development is unknown;
and (iv) the potential value of senescence-related gene signatures
for the diagnosis and/or prognosis of HCC has not yet been
assessed. A better understanding of these mechanisms could
contribute significantly to the discovery of novel molecular targets
for diagnosis and treatment of cirrhosis and HCC diseases, which
account for more than 500,000 deaths each year [27].
Here, we applied an integrative functional genomics approach
to explore the impact of senescence-related genes in liver cirrhosis
and HCC. We first generated genome-wide expression profiles of
in vitro hepatocellular senescence and immortality using a unique
senescence model based on the reprogramming of replicative
senescence in HCC-derived Huh7 cells [28]. By combined analysis
of in vitro, in vivo and in silico data, we provide a comprehensive list
of genes and cellular processes associated with hepatocellular
senescence and gain of cellular immortality in humans. We also
report on a robust 15-gene hepatocellular immortality signature
test that can efficiently differentiate HCC from cirrhosis.
Materials and Methods
Huh7 Clones
The establishment and culture conditions of senescence-
programmed C3 and G12, and immortal C1 and G11 clones
have been described previously [28]. Briefly, HCC-derived Huh7
cells were transfected with pcDNA3.1 (Invitrogen) or pEGFP-N2
(Clontech) vectors to obtain C1 and C3, and G11 and G12 clones,
respectively. Following transfection, single cell-derived colonies
were selected by G-418 sulfate (500 mg/ml; Gibco) treatment
under low-density clonogenic conditions. Senescence-programmed
C3 and G12 clones proliferated stably until population doubling
80 (PD80) and PD90, respectively. Then, they entered senescence
arrest as manifested by characteristic morphological changes,
abundant SA-b-Gal staining and ,5% 5-bromo-29-deoxyuridine
(BrdU) positivity after mitotic stimulation. Immortal C1 and G11
clones proliferated stably beyond PD140. For genome-wide
expression studies described here, senescence-arrested C3 and
G12 clones and immortal C1 and G11 clones were plated in
triplicate onto 15-cm diameter petri dishes, left in culture for three
days and collected for RNA extraction.
Other Cells and Cell Lines
Freshly isolated human hepatocytes were obtained commer-
cially (hNHEPSTM- Human Hepatocytes, Lonza Group, Basel,
Switzerland). Origin and culture conditions of HCC cell lines
Huh7, HepG2, Hep3B, Hep40, PLC/PRF/5, SNU-387, SNU-
398, SNU-423, SNU-449, SNU-475, FOCUS, Mahlavu and SK-
Hep-1 were previously described [29]. The fibrolamellar HCC
FLC4 cell line was provided by E. Galun (Hadassah, Israel) and
cultivated as described for other HCC cell lines. MRC-5 human
embryonic lung fibroblast cells (at PD45) were provided by R.
Pedeux (Grenoble, France) and maintained in culture as previ-
ously described [30].
Patients and Samples
Liver cirrhosis and HCC samples were collected from two
medical centers in Turkey. Tissue samples were snap frozen in
liquid nitrogen and stored at 280uC until use. Frozen tissues were
cut into 20 mm thick slices, and scraped into microtubes for RNA
extraction. Two 6 mm tissue slices were also cut for pathological
examination.
Ethics Statement
Clinical tissue sample collection was performed in accordance
with a study protocol pre-approved by Ethical Committees of
Ankara and Dokuz Eylul Universities, following written consent
from each patient.
RNA Extraction
Total RNA from cell lines and tissues was extracted using total
RNA isolation kit (Promega, Madison, USA) and NucleoSpin
RNA II Kit (MN Macherey-Nagel), respectively. DNase digestion
was performed following kit instructions. Cell line and tissue RNA
samples were analysed using Agilent Bioanalyzer.
Genome-wide Gene Expression Profiling
Affymetrix platform with GeneChip Human Genome U133
Plus 2.0 arrays were used for microarray analysis of both cell and
tissue RNA samples, following manufacturer instructions. Gene-
Chip Operating Software (Affymetrix) was used to collect and
store the microarray data. CEL files were uploaded to RMAEx-
press software to assess the quality of the arrays at the image level
Senescence Genes in Cirrhosis and Liver Cancer
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e64016
(http://rmaexpress.bmbolstad.com). Quality assessment of the
Affymetrix datasets was performed using affyPLM (http://www.
bioconductor.org). NUSE and RLE plots were drawn and outliers
with high deviation from the average probe intensity value were
excluded from further analyses. The microarray data reported in
this paper have been deposited in the Gene Expression Omnibus
(GEO) database under accession numbers of GSE17546 (Huh7
clones) and GSE17548 (cirrhosis and HCC tumor samples). All
cell line clones, 15 cirrhosis and 15 HCC tumor samples passed
RNA quality control (RNA Integrity Number, RIN.6.5) and
microarray quality control tests. RMA normalization and class
comparison analyses were performed using BRB-ArrayTools
developed by Dr. Richard Simon and BRB-ArrayTools Develop-
ment Team (http://linus.nci.nih.gov/BRB-ArrayTools.html; Ver-
sion 4.2.0).
Other Microarray Datasets
Two independent microarray datasets (GSE6764 and
GSE19665) were downloaded from Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo) and analyzed
by BRB Array tools after normalization with RMA.
Gene Set Enrichment Analysis
Gene set enrichment analyses (GSEA) were performed using
GSEA program of the Broad Institute [31]. For comparing in vitro
and in vivo GSEA profiles based on ‘‘C2_ALL’’ curated gene list, a
custom Matlab routine was applied to extract commonly
enriched gene sets. Pearson’s correlation coefficients were calcu-
lated using Matlab and Fisher’s exact test performed using
VassarStats (Vassarstats.net).
Cluster Analysis
Cluster 3.0 software [32] was used to assess unsupervised
clustering of datasets. First, data were adjusted by centering genes
and arrays separately based on mean values, and then the average
linkage clustering was applied to genes and arrays using a
correlation (uncentered) similarity metric. Cluster files were
visualized by Java Treeview [33].
Generation and Validation of a Senescence-based
Genomic Classifier
A senescence-based genomic classifier associated with differen-
tial diagnosis of HCC from cirrhosis was generated in BRB Array
Tools by Prediction Analysis of Microarrays [34] using data
reported by Wurmbach et al. [35] as a ‘‘training set’’. The
resulting classifier was tested using the nearest template prediction
(NTP) method [36] on a validation set constructed by combining
data reported here for Turkish patients with data from Deng et al.
[37] for Japanese patients. Nearest template prediction was
performed using NTP module [36] of GenePattern program
(http://www.broadinstitute.org/cancer/software/genepattern/)
using default parameters of the module. The final image was
generated using HeatMapImage module of the GenePattern and
the output of the NTP.
ATAD2 Expression Analysis by Quantitative PCR and
Western Blot Analyses
ATAD2, one of the 15 genes identified as a senescence-based
genomic classifier set was further analyzed for immortality-
associated over-expression in 14 HCC cell lines, as compared to
freshly isolated human hepatocytes and MRC-5 human embry-
onic lung fibroblast cells (PD44) at RNA and protein levels.
ATAD2 RNA expression was compared by quantitative real-time
PCR as previously described [38], using a specific primer pair
(forward: 59-AGG CTC ATT GGA AAA ACC T-39; reverse: 59-
CCT GCG GAA GAT AAT CGG TA-39). GAPDH was tested as
a housekeeping control gene using the following primers: forward:
59-GGC TGA GAA CGG GAA GCT TGT CAT-39; reverse: 59-
CAG CCT TCT CCA TGG TGG TGA AGA-39. The relative
expression of ATAD2 RNA in cell lines was calculated as
compared to that of normal hepatocytes. ATAD2 protein
expression was compared by western blot analysis of cell lysates,
as described previously [38], except that an anti-ATAD2 rabbit
polyclonal antibody (Sigma; cat. no: HPA019860) was used at
1:500 dilution as the primary antibody. Anti-calnexin rabbit
polyclonal antibody (Sigma; cat. no: C4731) was used at 1:10000
dilution for the loading control. The specificity of anti-ATAD2
antibody was validated by western blot analysis in Hep3B cells
after transfection with ATAD2-siRNA1 described by Caron et al.
[39]. For comparative analysis of ATAD2 protein expression
between immortal and senescent cells, senescence was induced in
Huh7 cells by Adriamycin (0.1 mM) treatment for three days as
previously described [40]. Briefly, Adriamycin- and DMSO
vehicle control-treated cells were maintained in culture for three
days. After confirming the senescence induction by morphological
examination and SA-b-Gal staining, cell lysates were subjected to
western blot analysis.
Results
Study Design
In order to analyze the participation of senescence-related genes
in human liver diseases, we designed a study protocol, as outlined
in Fig. 1. First, we generated genome-wide expression profiles of
Huh7 cell-line derived isogenic clones, as well as cirrhosis and
HCC tissues. The isogenic Huh7 clones that we used differed from
each other by their entry into replicative senescence arrest (at
PD80 to PD90) or lack of it (beyond PD150), resulting in a major
shift in tumorigenicity [28]. Next, we subjected in vitro and in vivo
gene expression data to gene set enrichment analysis (GSEA) to
identify and compare functional groups of genes associated with
senescence versus immortality, and cirrhosis versus HCC. Further-
more, we integrated our in vitro data with publicly available in vivo
data for a senescence-based comparison of progressive liver lesions
associated with hepatitis C virus (HCV)-induced HCC, and
established a senescence-based gene signature test for differential
diagnosis of HCC.
Gene Expression Profiles of Hepatocellular Senescence
in vitro
We profiled four independently established Huh7 clones,
subdivided into senescent and immortal phenotypes (i.e., two
clones from each phenotype) using gene expression analysis with
pangenomic 54 K Affymetrix microarrays. Three independent
biological replicates from each clone were used so that a total of 12
gene chips were performed. Hierarchical clustering of expression
values of the top 50 down- and up-regulated genes of each
phenotype segregated cell samples based on phenotypic assign-
ment, which suggested a common transcriptional consequence of a
switch between senescent and immortal fates (Fig. 2a). Next we
calculated GSEA enrichment scores [31] for six senescent cell
samples against six immortal cell samples using all curated gene
sets (‘‘C2_All’’) available at molecular signature database
(MSigDB; www.broadinstitute.org/gsea/). Based on significant
nominal P values (P,0.05), senescent and immortal phenotypes
were enriched in 598 and 113 gene sets, respectively (Data S1).
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Enriched gene sets included those participating in senescence-
and immortality-related cellular processes and pathways, provid-
ing evidence for transcriptional validation of senescent and
immortal phenotypes of Huh7 clones (Figs. 2b–e). As shown in
Fig. 2b, senescent Huh7 cells were enriched in gene sets that are
commonly up-regulated in senescent cells (‘‘FRIDMAN_SENES-
CENCE_UP’’) [10]. In addition, p53-responsive genes up-
regulated during replicative senescence arrest (‘‘TANG_SENES-
CENCE_TP53_TARGERTS_UP’’) [41], as well genes down-
regulated during immortalization in general (‘‘FRIDMAN_IM-
MORTALIZATION_DN’’) [10], and by human papillomavirus
31 (‘‘CHANG_IMMORTALIZED_BY_HPV_DN’’) [42], were
also up-regulated in senescent Huh7 clones. Interestingly, four
enriched gene sets were connected directly with either TERT or
telomeres (Fig. 2c–e). Genes down-regulated by TERT-mediated
immortalization (‘‘KANG_IMMORTALIZED_BY_-
TERT_DN’’) [43], as well as TERT-repressed target genes
(‘‘SMITH_TERT_TARGETS_DN’’) [44], were enriched in
senescent Huh7 clones (Fig. 2c). Furthermore, genes involved in
telomere end packaging (‘‘REACTOME_PACKAGING_OF_-
TELOMERE_ENDS’’; www.reactome.org) were up-regulated in
senescent Huh7 clones (Fig. 2d), while genes involved in telomere
extension (‘‘REACTOME_EXTENSION_OF_TELOMERES’’;
www.reactome.org) were enriched in immortal Huh7 clones
(Fig. 2e).
Association of Cirrhosis and Hepatocellular Carcinoma
with Senescent and Immortal Phenotypes Respectively
According to the protocol described in Fig. 1, next we
performed global gene expression analysis of 30 liver tissues,
including 15 cirrhosis and 15 HCC samples. All HCC samples
used in this study were obtained from cirrhotic patients (Table S1).
Hierarchical clustering with 50 most up- and down-regulated
genes were identified by GSEA-segregated tissue samples accord-
ing to their clinical phenotypes (Fig. 3a). Gene set enrichment
analysis of this in vivo data set using ‘‘C2_All’’ gene sets determined
that cirrhosis and HCC phenotypes are associated with 161 and
189 enriched gene sets, respectively (nominal P values,0.05; Data
S1). Among those gene sets, several were connected to senescence-
and immortality-related events. For example, cirrhosis was
enriched in p53-responsive genes up-regulated during replicative
senescence arrest (‘‘TANG_SENESCENCE_TP53_TAR-
GETS_UP’’) [41] (Fig. 3b). In contrast, HCC was enriched in
p53-responsive genes down-regulated during replicative senes-
cence arrest (‘‘TANG_SENESCENCE_TP53_TARGETS_DN’’)
[41] (Fig. 3c-top). Hepatocellular carcinoma tumors were also
enriched in the expression of genes involved in telomere extension
(‘‘REACTOME_EXTENSION_OF_TELOMERES’’; www.
reactome.org) (Fig. 3c-down).
Senescence-related Gene Networks in Cirrhosis and
Hepatocellular Carcinoma
The comparison of cell line and tissue enrichment scores based
on commonly enriched gene lists (Data S1) revealed a striking
correlation between senescence and cirrhosis (P,102115; r = 0.35),
as well as, between immortality and HCC (P= 86102114;
r = 0.72). This finding suggested that many functional gene
clusters overexpressed in cirrhosis and HCC were directly related
to the senescent and immortal phenotypes, respectively. To further
investigate this interesting correlation, we selected gene sets that
are co-enriched in four groups of biological samples (i.e. senescent
cells, immortal cells, cirrhotic tissues and HCCs) with a nominal P-
value less than 0.05. As shown in Fig. 4a, 34 of 74 common gene
sets (46%) were co-enriched in senescent cells and cirrhotic tissues,
whereas 39 (53%) were co-enriched in immortal cells and HCCs
(Two-tailed Fisher exact test, P = 2.6610220). Pearson correlation
values of co-enrichment scores were also significant (r = 0.97,
P= 2610243; Data S1). Gene sets up-regulated in cirrhosis/
senescence group were also up-regulated in non-tumor tissues as
opposed to those with tumors (four gene sets), or in less malignant
tumors versus more malignant tumors (11 gene sets). In contrast,
genes up-regulated in HCC/immortality group were associated
with tumors as opposed to non-tumor tissues (four out of five gene
sets), or in more malignant tumors as compared to less malignant
tumors (four gene sets). The HCC/immortality state was
characterized by an up-regulation of genes involved in DNA
repair (13 gene sets), cell cycle (seven gene sets), progenitor state
(two gene sets), telomere extension, DNA methylation and
branched chain amino acid metabolism. In contrast, genes
involved in cell signaling (six gene sets), lipid metabolism (four
gene sets), drug metabolism, retinol metabolism and glycolysis
were down-regulated (Fig. 4b).
Detailed analysis of genes involved in retinoid metabolism
[45,46] revealed that the expression of several genes encoding
critical enzymes catalyzing the synthesis of retinoic acid (the active
form of retinoids) was down-regulated in HCC tumors as
compared to cirrhotic liver tissue. There was also down-regulated
expression of genes involved in the storage of retinoids in tumors.
Down-regulated genes included two members of retinol dehydro-
Figure 1. Flow chart summarizing the study design. We analyzed
genome-wide gene expression in isogenic Huh7 clones with senescent
and immortal phenotypes, as well as in cirrhotic tissues and HCC
tumors. Both sets of data were subjected to GSEA using ‘‘C2-All’’
curated gene sets (‘‘C2_All’’) of molecular signature database (MSigDB;
www.broadinstitute.org/gsea/). In order to assess senescence- and
immortality-related gene expression changes during hepatocellular
carcinogenesis, genes differentially expressed in the model of cellular
senescence and immortality were identified and the evolution of their
expression profiles in pre-neoplastic and neoplastic liver lesions were
examined. Finally, a 15-gene senescence-based signature was generat-
ed using a training set of cirrhosis and HCC samples, and validated
using independently generated test datasets.
doi:10.1371/journal.pone.0064016.g001
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genases, four members of alcohol dehydrogenases, NADP(H)-
dependent retinol dehydrogenase/reductase (DHRS4) and b-
carotene 15,159-monooxygenase 1 (BCMO1), which are all
involved in the synthesis of retinal, the immediate precursor of
retinoic acid. Two genes involved in the synthesis of storage retinyl
esters, namely lecithin:retinol acyltransferase (LRAT) and patatin-
like phospholipase-4 (PNPLA4) were also down-regulated in HCC
cells (Fig. 5).
A Senescence-to-immortality Switch between Dysplasia
and Hepatocellular Carcinoma
Hepatocellular carcinogenesis is a multi-step process that is
usually manifested by progressive histological changes in the liver
from the cirrhosis stage to dysplasia followed by HCC [47]. Based
on close association of cirrhosis with senescence and that of HCC
with immortality, we hypothesized that the relative expression of
senescence- and immortality-associated genes in different liver
lesions may serve as a powerful means to dissect the timing of
transition from a senescent state to an immortal phenotype during
hepatocellular carcinogenesis. With this aim, we first generated a
list of ‘‘senescence-related genes’’ by comparing differential gene
expression between senescent and immortal Huh7 clones. Then,
we analyzed the expression patterns of these ‘‘senescence-related
genes’’ in a spectrum of hepatic lesions representing different steps
of HCC development. The list of senescence-related genes was
established by class comparison analysis of in vitro gene expression
data. Multivariate permutation tests identified 1220 genes
represented by 1813 probe sets with statistically significant
expression changes between senescent and immortal clones (P-
values,1027; fold-changes between senescent and immortal clones:
.2.0). The selected probe sets were then tested against a publicly
available gene expression dataset for tissues at different histological
stages of HCC development in HCV patients [35]. The tissue set
was composed of 10 normal liver samples, 13 cirrhotic tissues, 17
dysplastic lesions (originally described low- and high-grade
dysplasia cases combined), 17 early HCCs (originally described
very early and early HCC cases combined) and 18 advanced
HCCs (originally described advanced and very advanced cases
combined). Unsupervised clustering analysis applied to compare
these hepatic tissue samples (n = 75 in total) generated two major
clusters. Cluster 1 grouped together 39 out of the 40 non-HCC
samples (97.5%) and 1 out of the 35 (3%) HCC samples.
Conversely, cluster 2 was composed of 34 out of the 35 HCCs
(97%) and one of 40 (2.5%) of the non-HCC samples (Fig. 6).
Dysplastic lesions together with a subset of cirrhosis tissues formed
a homogenous subgroup under cluster 1, while normal liver
samples shared similarities with either cirrhotic or dysplastic tissue.
HCC samples formed several minor clusters, with a tendency of
early and advanced tumors to form distinct sub-clusters. The most
interesting finding of this analysis was the clustering of dysplastic
liver lesions together with cirrhosis samples that are in a senescent-
like state rather than with HCC samples assigned to an immortal-
like state.
Fifteen-gene Hepatocellular Immortality Signature for
Diagnosis of Hepatocellular Carcinoma
Based on remarkable clustering of tumor and non-tumor
tissues by the 1220 senescence-related genes, we then asked
whether we could select a smaller subset for discrimination of
HCC from cirrhosis. We used expression data from 35 HCC
and 13 cirrhosis samples from Wurmbach et al. [35] as a
‘‘training set’’. A PAM analysis using ‘‘nearest shrunken
centroid method’’ [34] identified 18 classifiers, composed of
six immortality-associated probe sets (representing five genes)
up-regulated in HCC tissues, ten senescence-associated probe
sets up-regulated in cirrhosis samples, and two senescence-
associated probe sets up-regulated in HCC (Fig. 7a). Fisher’s
exact test demonstrated a strong association of cirrhosis with
senescence and HCC with immortal phenotypes (P = 0.0015).
Then, we selected ten ‘‘cirrhosis- and senescence- associated’’
and five ‘‘HCC- and immortality-associated’’ genes (16 probe
sets in total) to construct a ‘‘hepatocellular immortality signature
set’’ (Table S2). Next, we tested the diagnostic value of the
signature genes using a ‘‘test set’’ composed of 45 tissue
samples, including 30 Turkish patient samples reported here
and 15 Japanese patient samples with publicly available
expression data [37]. Based on Nearest Template Prediction
method [36], the signature set was able to predict 100% (20/20)
of cirrhotic tissues with high confidence (FDR,0.05). Five of 25
HCC samples (20%) were unpredictable (FDR.0.05). Of the
remaining 20 HCC samples, 19 (95%) were predicted correctly
(Fig. 7b). Overall, the signature set provided high confidence
prediction (FDR,0.05) in 89% (40/45) of patients with 97.5%
(39/40) accuracy.
Association of ATAD2 RNA and Protein Expressions with
HCC and Cellular Immortality
The ATAD2, one of the fifteen hepatocellular immortality
signature genes, was of particular interest warranting further
investigation. The ATAD2 gene is mapped to chromosome 8q24
and codes for a predicted protein of 1,391 amino acids that
contains a double AAA ATPase domain and a bromodomain [48].
Figure 2. Gene expression profile analysis by gene set enrichment analysis assay (GSEA) established that senescent and immortal
Huh7 clones displayed differential expression of previously identified senescence- and immortality-associated gene sets
respectively, as well as those regulating telomere maintenance. (a) Heat map representation of the top 100 deregulated genes in immortal
Huh7 clones (Immortal) versus senescent Huh7 (Senescent) clones. Red: up-regulated; blue: down-regulated; arrow indicates TERT gene whose
expression is down-regulated in senescent clones. Previously identified gene sets (available at molecular signature database (MSigDB; www.
broadinstitute.org/gsea/) were screened to identify those that are differentially enriched in senescent or immortal Huh7 clones by the analysis of their
relative expression levels using GSEA method. (b) Gene set enrichment plots showing the up-regulated expression of two previously known
senescence-associated gene sets in senescent Huh7 clones, including genes that are commonly up-regulated in senescent cells (‘‘FRIDMAN_SE-
NESCENCE_UP’’) [10] and p53-responsive genes up-regulated during replicative senescence arrest (‘‘TANG_SENESCENCE_TP53_TARGERTS_UP’’) [41].
In addition, genes known to be down-regulated during immortalization in general (‘‘FRIDMAN_IMMORTALIZATION_DN’’) [10], and by human
papillomavirus 31 (‘‘CHANG_IMMORTALIZED_BY_HPV_DN’’) [42] were also up-regulated in senescent Huh7 clones. (c) Genes known to be down-
regulated by TERT-mediated immortalization (‘‘KANG_IMMORTALIZED_BY_TERT_DN’’) [43] and TERT-repressed target genes (‘‘SMITH_TERT_TAR-
GETS_DN’’) [44] were also enriched in senescent Huh7 clones. (d) Genes involved in telomere end packaging (‘‘REACTOME_PACKAGING_OF_TE-
LOMERE_ENDS’’; www.reactome.org) were upregulated in senescent Huh7 clones. (e) In contrast, genes involved in telomere extension
(‘‘REACTOME_EXTENSION_OF_TELOMERES’’; www.reactome.org) were enriched in immortal Huh7 clones. Enrichment scores (ES) are shown on the y-
axis. Positive and negative ES indicate enrichment in immortal and senescent Huh7 clones, respectively. X-axis bars represent individual genes of the
indicated gene sets. FDR: False discovery rate, p: nominal p-value. Three biological replicates from each clone were analyzed for genome-wide gene
expression using Affymetrix 54 K microarrays and normalized data were used for gene set enrichment analysis (GSEA).
doi:10.1371/journal.pone.0064016.g002
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The 8q24 locus displays frequent copy number gains in HCC [49],
and many other cancers [50]. Therefore, we selected ATAD2 as a
representative of our hepatocellular immortality signature to
validate its immortality- and HCC-associated expression by
additional experiments (Fig. 8). Freshly isolated normal adult
human hepatocytes and MRC-5 normal human fetal lung
fibroblasts (at PD44) were used as non-immortal control cells that
enter replicative senescence at around PD65 [30]. When
compared to normal hepatocytes, most HCC cell lines (n = 12/
14; 86%) displayed between two- and 20-fold higher ATAD2
mRNA expression. ATAD2 expression was less in MRC-5 cells
than hepatocytes (Fig. 8a). In order to further investigate ATAD2
expression, we tested its protein levels using a polyclonal rabbit
anti-ATAD2 antibody that recognized a single major band in
Hep3B HCC cells (Fig. 8b line Hep3B). The knock-down of
ATAD2 by siRNA1 [39] in these cells resulted in the loss of an
anti-ATAD2 immunoreactive band (Fig. 8b line Hep3B-si),
demonstrating the specificity of this antibody. ATAD2 protein
was undetectable in normal hepatocytes, but highly abundant in
six out of nine HCC cell lines, and easily detectable in the
remaining three (Fig. 8b). In order to further investigate
immortality-associated expression of ATAD2 in HCC cells, we
induced senescence arrest in Huh7 cells by 0.1 mM Adriamycin
treatment (Fig. 8c) as previously described [40], and compared
ATAD2 expression between Adriamycin-treated and control
Huh7 cells by western blot assay. We observed a drop in the
levels of ATAD2 proteins in senescence-arrested cells, as
compared to immortal Huh7 cells (Fig. 8d).
Discussion
Cellular senescence, considered for a long time to be an in vitro
phenomenon, emerged in recent years as a critical mechanism that
may play key roles in tissue aging as well as in the development of
different tumor types [1]. Here, we used a unique in vitro
hepatocellular senescence model to map senescence-related events
associated with in vivo HCC development. Our in vitro model
displayed a gene expression pattern compatible with replicative
senescence and TERT-induced cellular immortalization, in
conformation of our previously published observations [28]. We
were fortunate to find a high number of differentially expressed
genes between senescent and immortal clones that served as an
investigational tool to examine senescence-related transcriptional
events occurring during hepatocellular carcinogenesis. Based on
this, we provide here transcription-based evidence that cirrhosis
and HCC represent two opposite cellular phenotypes, senescence
and immortality, respectively. One of the major features of this
phenotypic opposition was the status of telomere maintenance
genes both between senescence and immortality, and cirrhosis and
HCC (Figs. 2, 3). The activation of TERT and telomere end
extension genes in immortal and HCC phenotypes is of particular
interest. Accelerated shortening of telomeres associated with a lack
of telomerase activity and high cell turnover during chronic
hepatitis has been recognized as a hallmark of cirrhosis several
years ago [16,21,51]. More recently, constitutional ‘‘loss-of-
function’’ type of telomerase (TERT or TERC genes) mutations
have been identified as a risk factor for cirrhosis [52,53]. In
Figure 3. Gene expression profile analysis by gene set enrichment analysis (GSEA) revealed the overexpression of senescence-
upregulated genes in cirrhosis, but over-expression of senescence-downregulated genes and telomere extension genes in HCC
tissues. (a) Heat map representation of the top 100 deregulated genes in hepatocellular carcinoma (HCC) versus cirrhosis samples. Red: up-
regulated; blue: down-regulated. Previously identified gene sets (available at molecular signature database (MSigDB; www.broadinstitute.org/gsea/)
were screened to identify those that are up-regulated in cirrhosis or HCC tissues by the analysis of their relative expression levels using GSEA method.
(b) Enrichment plot of p53-responsive genes up-regulated during replicative senescence arrest (‘‘TANG_SENESCENCE_TP53_TARGERTS_UP’’) [41]
showing over-expression in cirrhosis. (b) In contrast, p53-responsive genes down-regulated during replicative senescence arrest (‘‘TANG_SENES-
CENCE_TP53_TARGERTS_DN’’) [41] and those involved in telomere extension (‘‘REACTOME_EXTENSION_OF_TELOMERES’’; www.reactome.org) were
overexpressed in HCC tumors. Enrichment scores (ES) are shown on the y-axis. Positive and negative ES indicate enrichment in HCC and cirrhosis
samples, respectively. X-axis bars represent individual genes of the indicated gene sets. FDR: False discovery rate, p: nominal p-value. Fifteen cirrhosis
and fifteen HCC samples were analyzed for genome-wide gene expression using Affymetrix 54 K microarrays and normalized data were used for gene
set enrichment analysis (GSEA).
doi:10.1371/journal.pone.0064016.g003
Figure 4. Comparative analysis of gene sets enriched in Huh7
clones and diseased liver tissues associated cirrhosis with
senescence and HCC with immortality phenotypes, respective-
ly. (a). This analysis revealed also that cirrhosis/senescence- and HCC/
immortality-associated gene sets implicated distinct biological features
specific to each phenotype (b). (a) Scatter plot compares enrichment
scores of 74 gene sets commonly enriched in Huh7 clones (senescent or
immortal) and diseased liver tissues (cirrhosis or HCC) with a P value less
than 0.05. Thirty-nine gene sets (53%) were significantly enriched in
both HCC and immortal samples whereas 34 (46%) gene sets were
significantly enriched in both cirrhosis and senescent samples
(correlation value r = 0.97, p = 2610243). Only one gene set (1%) was
enriched in both HCC and senescent clones. (b) Distribution of
biological features defined by different gene sets in cirrhosis/
senescence (blue columns) and HCC/immortality (red columns)
phenotypes, respectively.
doi:10.1371/journal.pone.0064016.g004
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contrast to cirrhosis, HCC is known to reactivate TERT
expression [54], display high telomerase activity [24] and stabilize
telomeres [24,55]. Based on our present data supported by these
earlier reports, we propose that the activation of telomerase
activity is a key event for the gain of immortalized phenotype by
HCC cells. While working on this manuscript, recurrent and
activating TERT promoter mutations have been reported for
HCC cell lines [56], in strong support of our hypothesis.
The transition from a senescent state to an immortal state
coincided with early HCC lesions while dysplastic lesions
remained associated with cirrhosis and normal liver sample groups
indicating a non-immortal state. This pattern correlates with
malignant transformation in other tissues where pre-neoplastic
lesions display a senescent state from which neoplastic transfor-
mation emerges with a gain of phenotypic and molecular features
that are linked to an immortal state [57].
Co-enrichment of a high number of gene sets in cirrhotic tissues and
senescent cells as well as in HCCs and immortal cells was highly
interesting. This finding further emphasized the biological evidence for
a gain of immortal phenotype in human HCC. Among the gene sets
Figure 5. Comparative analysis of core enriched gene sets in Huh7 clones (senescent versus immortal) and diseased liver tissues
(cirrhosis versus HCC) indicated that retinoid metabolism genes (‘‘KEGG_RETINOL_METABOLISM’’) undergo systematic changes in
immortal cells and HCC, when compared to senescent cells and cirrhosis, respectively. (a) Heat map of core enriched retinoid metabolism
genes in Huh7 clones (left) and diseased liver tissues (right). Red: up-regulated; blue: down-regulated. Genes commonly deregulated in both Huh7
clones and diseased liver tissues are indicated with a dot. (b) A simplified view of retinoid metabolism. Enzyme-encoding genes down-regulated in
HCC are shown in blue. LRAT: lechitin retinol acetyl transferase, PNPLA4: patatin-like phospholipase domain containing-4, RDHs: retinol
dehydrogenases; ADHs: alcohol dehydrogenases; DHRS4: dehydrogenase/reductase (SDR family) member-4; BCMO1: beta-carotene 15,159-
monooxygenase-1; CYPs: Cytochrome P-450 family proteins; UGTs: UDP glucoronosyltransferases.
doi:10.1371/journal.pone.0064016.g005
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co-enriched in HCC and immortal cells, cell cycle and DNA repair
gene sets were at the top of the list (Fig. 4b). Up-regulation of cell cycle
and DNA repair genes in HCC is already known [35,58]; and the
overexpression of cell cycle genes in immortal cells is expected. The up-
regulation of DNA repair genes may serve as a mechanism to escape
from DNA damage-induced senescence arrest by increasing DNA
repair capacity of immortal or HCC cells.
Another interesting outcome of co-enrichment analysis was the
differential association of metabolism regulatory gene sets with
cirrhosis/senescence and HCC/immortality phenotypes. Co-enrich-
ment patterns revealed that genes involved in glycolysis as well as those
regulating drug, lipid and retinol metabolisms were down-regulated in
both immortal cells and HCC tumors. Down-regulation of genes
encoding the enzymes necessary for retinoic acid biosynthesis and
intracellular retinoid storage in HCC is of particular interest. Retinoic
acid, which is the active metabolite of retinoids, regulates a wide range
of biological processes including development, differentiation, prolifer-
ation, and apoptosis [59]. Normal hepatocytes together with hepatic
stellate cells play an indispensable role in the availability of retionic acid
and the storage of dietary retinoids [46]. Deregulated expression of
retinoid metabolism genes in HCC is expected to cause a deficit in the
synthesis of retinoic acid as well as in the storage of its metabolic
precursors (Fig. 5). Accordingly, reduced retinoid content has been
reported for HCC [46,60,61]. A deficit in cellular retinoic acid levels in
HCC cells, due to the expression changes reported here, may cause
severe perturbations in a multitude of cellular processes governed by
retinoic acid [59] by conferring a survival advantage to immortalized
HCC cells. Thus the restoration of retinoic acid availability in HCC
cells may adversely affect their survival. In favor of this hypothesis,
treatment with a synthetic analog of retinoic acid successfully prevented
second primary tumors in post-surgical HCC patients [62]. Thus, a
deficit in the availability of endogenous retinoic acid might facilitate
malignant transformation and tumor progression.
The most important risk factor for HCC is cirrhosis that is
present in 80 to 90% of patients with HCC. The patients with
cirrhosis develop HCC with a rate of 1.4–3.3% per year [27].
Therefore, the screening of cirrhotic patients by ultrasonography
of the liver combined with measurement of serum alpha-
fetoprotein levels every 6 to 12 months for HCC development is
recommended. However, the strength of the evidence supporting
Figure 6. Hierarchical clustering of 75 non-malignant and malignant liver tissue samples using 1813 senescence-associated gene
probe sets. Hepatocellular carcinoma and non-tumor liver tissues formed two distinct clusters (1 and 2) with the exception of one dysplasia and two
early HCC samples. The rows and columns represent genes and samples, respectively on the cluster map. Tissue samples are normal liver (pink),
cirrhosis (blue), dysplasia (yellow), early HCC (gray), and advanced HCC (black). Red: over-expressed, green: under-expressed probe set in the heat
map.
doi:10.1371/journal.pone.0064016.g006
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Figure 7. Generation and validation of a senescence-based gene classifier for differential diagnosis of cirrhosis and HCC. (a) Scatter
plot graphic compares relative expression levels (Log2 ratios) of 18 classifier probe sets representing 17 genes in Huh7 clones (immortal versus
senescent) and diseased liver tissues (HCC versus cirrhosis). Expression ratios of classifier genes showed a linear correlation (correlation value r = 0.7,
p = 0.0017) with ratios observed in Huh7 clones (immortal/senescent) and diseased liver tissues (HCC/cirrhosis). The classifier set was identified by
PAM analysis of 1813 senescence-associated probe sets using a training tissue set composed of cirrhosis (n = 13) and HCC (n = 35) samples described
by Wurmbach et al. [35]. Two probe sets which did not show expression patterns compatible with our in vivo senescence model were discarded to
define a final signature set composed of 16 probe sets representing 15 genes. (b) Validation of molecular prediction of HCC and cirrhosis by 15-
classifier gene set. Using the nearest template prediction method [36], we compared expression levels of sixteen probe sets representing 15 classifier
genes in a test tissue set composed of 20 cirrhosis and 25 HCC samples originating from Turkish (TR) patients described in this report, and Japanese
(JP) patients described elsewhere [37]. BH FDR (Benjamini-Hochberg false discovery rates) values (top), clinical versus predicted phenotypes (middle)
and heatmaps of classifier gene expression levels (bottom) are shown. The test provided a diagnostic result for 40 out of 45 samples (89%) with 97.5%
(39/40) accuracy.
doi:10.1371/journal.pone.0064016.g007
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the efficacy of surveillance is modest [63]. To overcome the lack of
efficacy, molecular HCC diagnosis techniques have been proposed
[64]. Previously reported molecular techniques used either
candidate genes [65] or genome-wide expression data
[35,54,66,67] to discriminate HCC from cirrhosis or dysplasia.
None of these molecular tests have yet to enter into surveillance
recommendations [64], probably because their prediction strength
did not reach the required level and/or they require simultaneous
analysis of dozens, even hundreds, of genes. Here, we provide a
highly promising hepatocellular immortality signature test for
HCC diagnosis. This novel molecular test requires the expression
profiles of only 15 genes. Moreover, this is a functional test based
on the analysis of senescence- and immortality-associated genes in
tissue samples. The test was able to correctly predict 100% of
cirrhosis cases. Twenty percent of HCCs displayed a borderline
gene expression pattern, so that the classifier was not able to
Figure 8. Association of ATAD2 RNA and protein expressions with HCC and cellular immortality. (a) Amplified expression of ATAD2 RNA
in HCC cell lines, as compared to normal hepatocytes and MRC-5 fibroblasts. Total RNAs were extracted from freshly isolated adult human
hepatocytes (Hepatocytes), MRC-5 human embryonic lung fibroblast cells (PD44) and 14 HCC cell lines; reverse transcribed into cDNA; and ATAD2
RNA was quantified by quantitative real-time PCR using specific primers. ATAD2 expression values for each sample were normalized with
housekeeping gene GAPDH RNA values. Relative expression of ATAD2 in MRC-5 and HCC cell lines was expressed in reference to its expression in
hepatocytes. Averages of three measurements. Error bars: SD. (b) Amplified expression of ATAD2 protein in HCC cells, as compared to normal
hepatocytes. Total proteins were extracted from freshly isolated adult human hepatocytes (Hepatocytes), untreated (Hep3B) and ATAD2 siRNA1-
treated (Hep3B-si) Hep3B and eight other HCC cell lines, and ATAD2 protein levels were tested by western blot analysis using a specific anti-ATAD2
antibody (ATAD2). Western blot analysis of calnexin protein from the same blots was used for loading control (Calnexin). (c, d) Comparative analysis
by western blotting demonstrated that ATAD2 protein is overexpressed in immortal Huh7 cells as compared to senescence-arrested Huh7 cells. (c)
Huh7 cells were treated with Adriamycin (0.1 mM) or DMSO (Control) for three days and subjected to senescence assay by SA-b-Gal staining (blue).
Cells were counterstained with fast red (red). (d) Total protein was extracted from control and Adriamycin-treated Huh7 cells, and ATAD2 and
Calnexin proteins were tested as described in (b).
doi:10.1371/journal.pone.0064016.g008
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categorize them as HCC or cirrhosis. However, the test was able
to predict the remaining HCC patients with 97.5% accuracy.
One of the hepatocellular immortality signature genes is
ATAD2. By using techniques independent of microarray tools,
we demonstrated in vitro that ATAD2 RNA and protein that are
weakly present or not expressed in normal hepatocytes and
fibroblasts are highly expressed in HCC cell lines. We also showed
that ATAD2 protein levels go down in association with
Adriamycin-induced senescence arrest in otherwise immortal
Huh7 cells. ATAD2 protein is likely to be a chromatin modifier
[48]. Its exact cellular function is unknown, but its overexpression
in immortal cells, and in many cancer types [39,68] is in favor of
an essential role in tumor malignancy. Finally, our preliminary
findings suggest that hepatocellular immortality signature genes
such as ATAD2 may serve as promising HCC biomarkers.
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